MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Remote recruitment of hyposmic participants identifies biomarkers related to neuronal alpha-synuclein disease

    E. Brown, A. Siderowf, T. Simuni, T. Sherer, M. Brumm, C. Caspell-Garcia, R. Kurth, C. Gochanour, M. Marshall, M. Korell, C. Stanley, L. Concha, C. Soto, K. Marek, C. Tanner (San Francisco, USA)

    Objective: To evaluate the proportion of people with dopaminergic deficit and positive alpha-synuclein seed amplification assay (aSyn SAA) among a remotely identified group of hyposmic…
  • 2024 International Congress

    Developing a selection framework for digital measures of Parkinson’s disease progression for the EJS ACT-PD trial

    R. Ellis-Doyle, ML. Zeissler, C. Gonzalez-Robles, M. Bartlett, S. Collins, S. Del-Din, S. Haar, M. Hu, A. Jha, C. Lambert, A. Noyce, R. Petty, K. Pushparatnam, L. Rochester, C. Siu, G. Mills, A. Schrag, T. Foltynie, C. Carroll, A. Yarnall (London, United Kingdom)

    Objective: To develop a selection process for digital measures (DMs) to include as exploratory outcome measures of Parkinson’s disease (PD) progression in a platform disease…
  • 2024 International Congress

    Changes in Gut Microbiome of Parkinson’s disease Patients using Photobiomodulation Therapy

    B. Bicknell, G. Herkes, A. Liebert, H. Kiat (, Westmead, Australia)

    Objective: To assess changes in the gut microbiome composition in a small cohort of clinical trial participants using photobiomodulation (light therapy) over a five-year period…
  • 2024 International Congress

    First-In-Human Single and Multiple Ascending Dose Trial Design of LY3962681, a Novel Intrathecally Delivered siRNA Targeting α-synuclein mRNA for the Treatment of Patients with Parkinson’s Disease

    T. Lewis, B. Calamini, L. Verselis, M. Lowrey, L. Shaughnessy, J. Deranick, M. Dieter, M. Krautkramer, O. Uspenskaya, J. Sevigny (New York, USA)

    Objective: Development of a Phase 1 clinical trial evaluating LY3962681, a novel, intrathecally delivered siRNA directly targeting α-synucleinmRNA (SNCA) to reduce α-synuclein protein (ASYN), for the treatment of…
  • 2024 International Congress

    Parkinson Patients` Motor and Cognitive Functions are Improved by High Intensity LSVT®BIG Physiotherapy – a Randomized Prospective Pilot Trial

    B. Wimmer, B. Budeus, M. Katzer, C. Preiner, T. Wächter, K. Seppi, U. Bogdahn (Innsbruck, Austria)

    Objective: The objective of this pilot study was to evaluate the potential efficacy of high intensity physiotherapy LSVT®BIG on motor and non-motor functions of PD…
  • 2024 International Congress

    Effect of Levodopa therapy in Hypokinetic Dysarthria in Parkinson’s Disease

    E. Smaoui, N. Farhat, S. Daoud, K. Moalla, N. Bouattour, M. Damak, C. Mhiri (Sfax, Tunisia)

    Objective: The objective of this study was to assess the possible changes in acoustic speech parameters in a cohort of PD patients after acute levodopa…
  • 2024 International Congress

    A Comparative Bioavailability Study between a Marketed Capsule-based Levodopa Dry Powder Inhaler and a New Pre-filled Levodopa Dry Powder Inhaler

    T. van Laar, F. Grasmeijer, M. Hoppentocht (Groningen, Netherlands)

    Objective: The primary objective was to determine the comparative bioavailability between a marketed and a new levodopa dry powder inhaler (DPI) with an enhanced usability…
  • 2024 International Congress

    Estimating the Proportion of Parkinson’s Disease Clinical Trial Subjects Who Showed No Measurable MDS-UPDRS Motor Score Progression Over 1 Year

    M. Pang, J. Edgerton, L. Zhu, S. Belachew, D. Taylor, C. Kanzler, M. Yang, F. Nahab, C. Shen (Cambridge, USA)

    Objective: To determine what percentage of subjects with early Parkinson’s disease demonstrated no measurable worsening of MDS-UPDRS motor scores over 52 weeks in a Phase…
  • 2024 International Congress

    Opicapone as Add-on to Levodopa in Parkinson’s Patients without Motor Complications: Preliminary Data from EPSILON

    J. Ferreira, O. Rascol, F. Stocchi, A. Antonini, J. Moreira, G. Castilla-Fernández, J. Rocha, J. Holenz, W. Poewe (Lisbon, Portugal)

    Objective: The EPSILON study aimed to explore the potential of opicapone (OPC) to enhance the clinical benefit of levodopa/dopa decarboxylase inhibitor (DDCi) in patients with…
  • 2024 International Congress

    A matching-adjusted indirect comparison of efficacy and safety for safinamide versus rasagiline as adjunctive treatment to levodopa in Chinese patients with Parkinson’s disease

    Y. Tan, Q. Wei, P. Xu, E. Tao, L. Wang, C. Cattaneo, H. Shang, S. Chen (Shanghai, China)

    Objective: To compare  efficacy and safety of safinamide and rasagiline as adjunctive treatment to levodopa in Chinese patients with Parkinson’s disease (PD) by matching-adjusted indirect…
  • « Previous Page
  • 1
  • …
  • 69
  • 70
  • 71
  • 72
  • 73
  • …
  • 1554
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Yerba Mate (Ilex paraguaiensis) protects dopaminergic neurons degeneration and improve their maturation in culture
  • #26133 (not found)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley